Home/Pipeline/CaPtivaX Nasal Influenza Vaccine

CaPtivaX Nasal Influenza Vaccine

Influenza Prevention

Pre-clinicalActive

Key Facts

Indication

Influenza Prevention

Phase

Pre-clinical

Status

Active

Company

CaPtivate Pharmaceuticals

About CaPtivate Pharmaceuticals

CaPtivate Pharmaceuticals is a small, private biotech firm leveraging its calcium phosphate nanoparticle technology to create novel vaccine adjuvants and delivery systems. Its platform, branded CaPtivaX for vaccines and CaPteraX for therapeutics, aims to enhance immune responses, including T-cell activation, and can be administered via parenteral or mucosal routes. The company pursues internal development programs, such as nasal and pandemic influenza vaccines, while also offering its formulation services and technology for partnership opportunities in vaccine development.

View full company profile

Therapeutic Areas

Infectious Disease Veterinary Health

Other Influenza Prevention Drugs

Drug	Company	Phase	Status
mRNA-based Broad Flu Vaccine	Micron Biomedical	Pre-clinical	Active
Next-Generation Influenza Vaccines	Fluart Innovative Vaccines	Not Disclosed	Active
HD-MAP Influenza Vaccine	Vaxxas	Phase 2/3	Active
IRT Platform (e.g., Influenza)	Biological Mimetics	Research/Pre-clinical	Active
Replicon RNA Influenza Vaccine	BIKEN Group	Preclinical/Development	Partnership Development with VLPT Japan and Denka
Innovative Influenza Vaccine	Livzon Pharmaceutical	Phase 1	Completed patient enrollment in Phase I
CS-2606 mRNA Multi-valent Influenza Vaccine	CanSino Biologics	Pre-clinical	Active